calendar
139 catalysts · 34 phase 2 completion · 24 phase 1 completion · 21 phase 1 2 completion · 17 phase 2 initiation · 13 phase 1 initiation · 12 phase 1 2 initiation
next 91 dayslessmore
MonWedFri
139 catalysts · 34 phase 2 completion · 24 phase 1 completion · 21 phase 1 2 completion · 17 phase 2 initiation · 13 phase 1 initiation · 12 phase 1 2 initiation
Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease
Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease
Therapy area: Oncology. Indication: Lung Adenocarcinoma, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Solid Tumor, Squamous Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Uterine Cancer
Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Nodal Marginal Zone B-Cell Lymphoma, Non-Hodgkin Lymphoma, Primary Mediastinal B-Cell Lymphoma, Splenic Marginal Zone B-Cell Lymphoma
Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Therapy area: Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma)
Therapy area: Oncology. Indication: Rectal Cancer
Therapy area: Oncology. Indication: B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Therapy area: Oncology. Indication: Follicular Thyroid Cancer, Papillary Thyroid Cancer, Thyroid Cancer
Therapy area: Oncology. Indication: Breast Cancer, Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)
Therapy area: Oncology. Indication: Small-Cell Lung Cancer
Therapy area: Oncology. Indication: Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Therapy area: Oncology. Indication: Advanced Malignancy, Diffuse Large B-Cell Lymphoma, Head And Neck Squamous Cell Carcinoma (HNSC), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Solid Tumor
Therapy area: Oncology. Indication: Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC)
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease)
Therapy area: Oncology. Indication: Advanced Malignancy, Solid Tumor
Therapy area: Oncology. Indication: Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma
Therapy area: Oncology. Indication: Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Follicular Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), T-Cell Lymphomas
Therapy area: Oncology. Indication: Neuroendocrine Cancer, Small-Cell Lung Cancer, Solid Tumor
Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Therapy area: Oncology. Indication: Thyroid Cancer
Therapy area: Oncology. Indication: Neuroendocrine Cancer, Neuroendocrine Carcinoma, Small-Cell Lung Cancer
Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Squamous Non-Small Cell Lung Cancer
Therapy area: Oncology. Indication: Solid Tumor, Squamous Non-Small Cell Lung Cancer
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Therapy area: Oncology. Indication: Lung Cancer
Therapy area: Oncology. Indication: Blood Cancer, Hematological Tumor, Leukemia, Lymphoma
Therapy area: Oncology. Indication: Colorectal Cancer
Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Therapy area: Oncology. Indication: Ovarian Cancer
Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Recurrent Glioblastoma Multiforme (GBM)
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Therapy area: Gastrointestinal, Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma), Hepatocellular Carcinoma, Liver Cancer, Liver Cirrhosis, Metastatic Liver Cancer
Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Solid Tumor
Therapy area: Oncology. Indication: Pancreatic Cancer
Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer
Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Solid Tumor
Therapy area: Oncology. Indication: Solid Tumor
Therapy area: Oncology. Indication: Metastatic Pancreatic Cancer, Pancreatic Cancer
Therapy area: Oncology. Indication: Nasopharyngeal Cancer
Therapy area: Oncology. Indication: Hepatocellular Carcinoma, Liver Cancer
Therapy area: Oncology. Indication: Cervical Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer, Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hepatocellular Carcinoma, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Pleural Mesothelioma, Melanoma, Non-Small Cell Lung Carcinoma, Oral Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Re
Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Plasma Cell Neoplasm, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma
Therapy area: Oncology, Toxicology. Indication: Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome), Colon Tumor
Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Prostate Cancer, Prostate Cancer
Therapy area: Genito Urinary System, Oncology. Indication: Bladder Cancer, Bladder Carcinoma, Kidney Cancer (Renal Cell Cancer), Metastatic Transitional (Urothelial) Tract Cancer, Renal Stones/Calculi, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer
Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hypopharyngeal Cancer, Laryngeal Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Recurrent Head And Neck Squamous Cell Carcinoma